These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24139476)

  • 1. Persistence of measles neutralizing antibody related to vaccine and natural infection acquired before HIV infection.
    Isa MB; Pavan JV; Sicilia Don P; Grutadauria S; Martinez LC; Giordano MO; Masachessi G; Barril PA; Nates SV
    Epidemiol Infect; 2014 Aug; 142(8):1708-12. PubMed ID: 24139476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age.
    Gans HA; Yasukawa LL; Sung P; Sullivan B; DeHovitz R; Audet S; Beeler J; Arvin AM
    J Infect Dis; 2013 Feb; 207(4):574-82. PubMed ID: 23300162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles Immunity at 4.5 Years of Age Following Vaccination at 9 and 15-18 Months of Age Among Human Immunodeficiency Virus (HIV)-infected, HIV-exposed-uninfected, and HIV-unexposed Children.
    Mutsaerts EAML; Nunes MC; van Rijswijk MN; Klipstein-Grobusch K; Otwombe K; Cotton MF; Violari A; Madhi SA
    Clin Infect Dis; 2019 Aug; 69(4):687-696. PubMed ID: 30418528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunoglobulin G subclass profiles induced by measles virus in vaccinated and naturally infected individuals.
    Isa MB; Martínez L; Giordano M; Passeggi C; de Wolff MC; Nates S
    Clin Diagn Lab Immunol; 2002 May; 9(3):693-7. PubMed ID: 11986279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection.
    Nair N; Moss WJ; Scott S; Mugala N; Ndhlovu ZM; Lilo K; Ryon JJ; Monze M; Quinn TC; Cousens S; Cutts F; Griffin DE
    J Infect Dis; 2009 Oct; 200(7):1031-8. PubMed ID: 19702505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus.
    Christenson B; Böttiger M
    Vaccine; 1994 Feb; 12(2):129-33. PubMed ID: 8147093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine-induced measles virus-specific T cells do not prevent infection or disease but facilitate subsequent clearance of viral RNA.
    Lin WH; Pan CH; Adams RJ; Laube BL; Griffin DE
    mBio; 2014 Apr; 5(2):e01047. PubMed ID: 24736226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of titers of antibody against measles virus in sera of vaccinated and naturally infected Japanese individuals of different age groups.
    Itoh M; Okuno Y; Hotta H
    J Clin Microbiol; 2002 May; 40(5):1733-8. PubMed ID: 11980952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine.
    Garly ML; Balé C; Martins CL; Monteiro M; George E; Kidd M; Dias F; Aaby P; Whittle HC
    Vaccine; 2001 Feb; 19(15-16):1951-9. PubMed ID: 11228365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in measles serostatus among HIV-infected Zambian children initiating antiretroviral therapy before and after the 2010 measles outbreak and supplemental immunization activities.
    Rainwater-Lovett K; Nkamba HC; Mubiana-Mbewe M; Bolton-Moore C; Moss WJ
    J Infect Dis; 2013 Dec; 208(11):1747-55. PubMed ID: 23911708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles seroprevalence and vaccine response in HIV-infected adults.
    Wallace MR; Hooper DG; Graves SJ; Malone JL
    Vaccine; 1994 Oct; 12(13):1222-4. PubMed ID: 7839728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.
    Haralambieva IH; Ovsyannikova IG; O'Byrne M; Pankratz VS; Jacobson RM; Poland GA
    Vaccine; 2011 Jun; 29(27):4485-91. PubMed ID: 21539880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa.
    Benn CS; Aaby P; Balé C; Olsen J; Michaelsen KF; George E; Whittle H
    Lancet; 1997 Jul; 350(9071):101-5. PubMed ID: 9228962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study.
    Moss WJ; Scott S; Mugala N; Ndhlovu Z; Beeler JA; Audet SA; Ngala M; Mwangala S; Nkonga-Mwangilwa C; Ryon JJ; Monze M; Kasolo F; Quinn TC; Cousens S; Griffin DE; Cutts FT
    J Infect Dis; 2007 Aug; 196(3):347-55. PubMed ID: 17597448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of measles antibodies after 2 doses of measles vaccine in a postelimination environment.
    LeBaron CW; Beeler J; Sullivan BJ; Forghani B; Bi D; Beck C; Audet S; Gargiullo P
    Arch Pediatr Adolesc Med; 2007 Mar; 161(3):294-301. PubMed ID: 17339511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemagglutination inhibition antibody levels one year after natural measles infection and vaccination.
    Eghafona NO; Ahmad AA; Ezeokoli CD; Emejuaiwe SO
    Microbios; 1991; 67(274):33-6. PubMed ID: 1758308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
    Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum anti-tetanus and measles antibody titres in Ugandan children aged 4 months to 6 years: implications for vaccine programme.
    Warrener L; Bwogi J; Andrews N; Samuel D; Kabaliisa T; Bukenya H; Brown K; Roper MH; Featherstone DA; Brown D
    Epidemiol Infect; 2018 Jul; 146(9):1151-1156. PubMed ID: 29739482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on the neutralization capacity of different types of human measles virus vaccine and the epidemic strains].
    Feng Y; Lu YY; Yan JY; Jiang XH; Shi W; Xu CP; Li Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Nov; 28(11):1123-6. PubMed ID: 18396671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.
    Fiebelkorn AP; Coleman LA; Belongia EA; Freeman SK; York D; Bi D; Kulkarni A; Audet S; Mercader S; McGrew M; Hickman CJ; Bellini WJ; Shivakoti R; Griffin DE; Beeler J
    J Infect Dis; 2016 Apr; 213(7):1115-23. PubMed ID: 26597262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.